Opinion Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2023; 14(7): 939-941
Published online Jul 15, 2023. doi: 10.4239/wjd.v14.i7.939
Access to novel anti-diabetic agents in resource limited settings: A brief commentary
Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang
Poobalan Naidoo, Department of Internal Medicine, Nelson R Mandela, School of Medicine, University of Kwa-Zulu Natal, Durban 4001, Kwa-Zulu Natal, South Africa
Kiolan Naidoo, Department of Law, University of South Africa, Pretoria 3, Gauteng, South Africa
Sumanth Karamchand, Department of Cardiology, University of Stellenbosch and Tygerberg Hospital, Stellenbosch 7600, Western Cape, South Africa
Rory F Leisegang, Department of Pharmacometrics, Upsala University, Uppsala 751 04, Sweden
Author contributions: All authors contributed equally to this manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Poobalan Naidoo, BPharm, MBChB, MMedSc (Pharmacology), DipHIVMan (CMSA), Medical Registrar and Academic Research, Doctor, Department of Internal Medicine, Nelson R Mandela, School of Medicine, University of Kwa-Zulu Natal, Sydney Road, Umbilo, Durban 4001, Kwa-Zulu Natal, South Africa. poobalan1naidoo@yahoo.com
Received: October 13, 2022
Peer-review started: October 13, 2022
First decision: November 27, 2022
Revised: December 31, 2022
Accepted: June 13, 2023
Article in press: June 13, 2023
Published online: July 15, 2023
Processing time: 272 Days and 10.5 Hours
Core Tip

Core Tip: The manuscript addresses the problem of access to novel anti-diabetic agents in resource limited settings. Niching therapies for use in those with highest major adverse cardiovascular risk, may limit budget impact for funders. To improve access, and reduce morbidity and mortality, requires alignment amongst key stakeholders including patient advocacy groups, health care professional councils, national departments of health, the pharmaceutical industry, treasury and finance departments.